Background: Currently, there is an unmet medical need for long-term effective treatment of inoperable, gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) 177 Lu-DOTATATE (7.4 GBq x 4 at 8 ± 1-week intervals) plus supportive care with 30 mg Octreotide LAR will be compared to 60 mg Octreotide LAR (injections at 4-week intervals). The primary objective is Progression Free Survival (PFS) between the two arms. Objective tumour assessment is performed every 12 weeks until PFS. Tumor progression is assessed with an independent image reading center. The main secondary objectives are to compare Objective Response Rate, Overall Survival (OS), and Time to Tumour Progression between the two arms, and to assess safety, tolerability and health-related quality of life. Dosimetry, pharmacokinetics and ECG evaluations in patients treated with 177 Lu-DOTATATE will also be performed. The study will randomize 230 patients (1:1 to each arm). The OS period includes 18-month accrual plus 5 years follow-up. There are 35 European and 15 USA sites involved. Recruitment is ongoing, and the first patient was enrolled in July 2012. An independent Data Safety Monitoring Board (DSMB) is supervising the conduct of the study and regularly assesses the safety outcome.
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